56614 Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices 

a bulk manufacturer of the basic classes of controlled substances listed in 

schedules I and II: 

Drug Schedule 

Methcathinone (1237) .................................................................................................................................................................................. I 

N-Ethylamphetamine (1475) ........................................................................................................................................................................ I 

N,N-Dimethylamphetamine (1480) ............................................................................................................................................................... I 

4-Methylaminorex (cis isomer) (1590) ......................................................................................................................................................... I 

Alpha-ethyltryptamine (7249) ....................................................................................................................................................................... I 

Lysergic acid diethylamide (7315) ............................................................................................................................................................... I 

2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) ................................................................................................................................ I 

Tetrahydrocannabinols (7370) ..................................................................................................................................................................... I 

Mescaline (7381) .......................................................................................................................................................................................... I 

4-Bromo-2,5-dimethoxyamphetamine (7391) ............................................................................................................................................... I 

4-Bromo-2,5-dimethoxyphenethylamine (7392) ........................................................................................................................................... I 

4-Methyl-2,5-dimethoxyamphetamine (7395) ............................................................................................................................................... I 

2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................. I 

2,5-Dimethoxy-4-ethylamphetamine (7399) ................................................................................................................................................. I 

3,4-Methylenedioxyamphetamine (7400) ..................................................................................................................................................... I 

N-Hydroxy-3,4-methylenedioxyamphetamine (7402) ................................................................................................................................... I 

3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................ I 

3,4-Methylenedioxymethamphetamine (MDMA) (7405) .............................................................................................................................. I 

4-Methoxyamphetamine (7411) ................................................................................................................................................................... I 

Alpha-methyltryptamine (7432) .................................................................................................................................................................... I 

Bufotenine (7433) ......................................................................................................................................................................................... I 

Diethyltryptamine (7434) .............................................................................................................................................................................. I 

Dimethyltryptamine (7435) ........................................................................................................................................................................... I 

Psilocybin (7437) .......................................................................................................................................................................................... I 

Psilocyn (7438) ............................................................................................................................................................................................. I 

5-Methoxy-N,N-diisopropyltryptamine (7439) ............................................................................................................................................... I 

N-Ethyl-1-phenylcyclohexylamine (7455) ..................................................................................................................................................... I 

1-(1-Phenylcyclohexyl)pyrrolidine (7458) ..................................................................................................................................................... I 

1-Phenylcyclohexylamine (7460) ................................................................................................................................................................. I 

1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ................................................................................................................................................ I 

Normorphine (9313) ..................................................................................................................................................................................... I 

Methamphetamine (1105) ............................................................................................................................................................................ II 

Phencyclidine (7471) .................................................................................................................................................................................... II 

Phenylacetone (8501) .................................................................................................................................................................................. II 

1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................. II 

Cocaine (9041) ............................................................................................................................................................................................. II 

Codeine (9050) ............................................................................................................................................................................................. II 

Dihydrocodeine (9120) ................................................................................................................................................................................. II 

Dihydromorphine (9145) ............................................................................................................................................................................... II 

Ecgonine (9180) ........................................................................................................................................................................................... II 

Meperidine intermediate-B (9233) ................................................................................................................................................................ II 

Noroxymorphone (9668) .............................................................................................................................................................................. II 

The company plans to manufacture 

high purity drug standards used for 

analytical applications only in clinical, 

toxicological, and forensic laboratories. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Alltech Associates, Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Alltech Associates Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: September 22, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–22875 Filed 9–26–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 28, 2008 and 

published in the Federal Register on 

May 2, 2008 (73 FR 24313), Lin Zhi 

International Inc., 687 North Pastoria 

Avenue, Sunnyvale, California 94085, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

.......................................................

Tetrahydrocannabinols (7370) ..... I 

3,4-Methylenedioxymethamphetamine (MDMA) (7405).I 

Cocaine (9041) ............................. II 

Oxycodone (9143) ........................ II 

Hydrocodone (9193) ..................... II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

The company plans to manufacture 

the listed controlled substances as bulk 

reagents for use in drug abuse testing. 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices 56615 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of Lin 

Zhi International Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Lin Zhi International Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: September 22, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–22877 Filed 9–26–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated May 15, 2008 and 

published in the Federal Register on 

May 27, 2008 (73 FR 30418), Siegfried 

(USA), Inc., Industrial Park Road, 

Pennsville, New Jersey 08070, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Oripavine (9330), a basic class of 

controlled substance listed in schedule 

II. 

The company will use the above 

listed controlled substance in the 

manufacture of other controlled 

substance intermediates for sale to its 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Siegfried (USA), Inc. to manufacture the 

listed basic class of controlled substance 

is consistent with the public interest at 

this time. DEA has investigated 

Siegfried (USA), Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: September 22, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–22879 Filed 9–26–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Occupational Safety and Health 

Administration 

[Docket No. OSHA–2008–0023] 

Telecommunications; Extension of the 

Office of Management and Budget’s 

(OMB) Approval of Information 

Collection (Paperwork) Requirements 

AGENCY: Occupational Safety and Health 

Administration (OSHA), Labor. 

ACTION: Request for public comment. 

SUMMARY: OSHA solicits comments 

concerning its proposal to extend OMB 

approval of the information collection 

requirement contained in the Standard 

on Telecommunications (29 CFR 

1910.268). The purpose of this 

requirement is to ensure that employees 

have been trained as required by the 

Standard to prevent risk of death or 

serious injury. 

DATES: Comments must be submitted 

(postmarked, sent, or received) by 

November 28, 2008. 

ADDRESSES: Electronically: You may 

submit comments and attachments 

electronically at http:// 

www.regulations.gov, which is the 

Federal eRulemaking Portal. Follow the 

instructions online for submitting 

comments. 

Facsimile: If your comments, 

including attachments, are not longer 

than 10 pages, you may fax them to the 

OSHA Docket Office at (202) 693–1648. 

Mail, hand delivery, express mail, 

messenger, or courier service: When 

using this method, you must submit 

three copies of your comments and 

attachments to the OSHA Docket Office, 

Docket No. OSHA–2008–0023, U.S. 

Department of Labor, Occupational 

Safety and Health Administration, 

Room N–2625, 200 Constitution 

Avenue, NW., Washington, DC 20210. 

Deliveries (hand, express mail, 

messenger, and courier service) are 

accepted during the Department of 

Labor’s and Docket Office’s normal 

business hours, 8:15 a.m. to 4:45 p.m., 

e.t. 

Instructions: All submissions must 

include the Agency name and OSHA 

docket number for the ICR (OSHA– 

2008–0023). All comments, including 

any personal information you provide, 

are placed in the public docket without 

change, and may be made available 

online at http://www.regulations.gov. 

For further information on submitting 

comments see the ‘‘Public 

Participation’’ heading in the section of 

this notice titled ‘‘SUPPLEMENTARY

INFORMATION.’’ 

Docket: To read or download 

comments or other material in the 

docket, go to http://www.regulations.gov 

or the OSHA Docket Office at the 

address above. All documents in the 

docket (including this Federal Register 

notice) are listed in the http:// 

www.regulations.gov index; however, 

some information (e.g., copyrighted 

material) is not publicly available to 

read or download through the Web site. 

All submissions, including copyrighted 

material, are available for inspection 

and copying at the OSHA Docket Office. 

You may also contact Theda Kenney at 

the address below to obtain a copy of 

the ICR. 

FOR FURTHER INFORMATION CONTACT: 

Theda Kenney or Todd Owen, 

Directorate of Standards and Guidance, 

OSHA, U.S. Department of Labor, Room 

N–3609, 200 Constitution Avenue, NW., 

Washington, DC 20210; telephone (202) 

693–2222. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Department of Labor, as part of its 

continuing effort to reduce paperwork 

and respondent (i.e., employer) burden, 

conducts a preclearance consultation 

program to provide the public with an 

opportunity to comment on proposed 

and continuing information collection 

requirements in accordance with the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 3506(c)(2)(A)). This program 

ensures that information is in the 

desired format, reporting burden (time 

and costs) is minimal, collection 

instruments are clearly understood, and 

OSHA’s estimate of the information 

collection burden is accurate. The 

Occupational Safety and Health Act of 

1970 (the OSH Act) (29 U.S.C. 651 et 

seq.) authorizes information collection 

by employers as necessary or 

appropriate for enforcement of the Act 

or for developing information regarding 

the causes and prevention of 

mstockstill on PROD1PC66 with NOTICES